Compare RWT & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RWT | DRTS |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | Israel |
| Employees | 351 | 121 |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.5M | 641.6M |
| IPO Year | N/A | N/A |
| Metric | RWT | DRTS |
|---|---|---|
| Price | $5.26 | $9.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $6.82 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 1.2M | 607.6K |
| Earning Date | 04-29-2026 | 05-18-2026 |
| Dividend Yield | ★ 12.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.59 | N/A |
| Revenue Next Year | $22.21 | $699.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.00 | $2.81 |
| 52 Week High | $6.97 | $10.80 |
| Indicator | RWT | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 31.02 | 64.89 |
| Support Level | $5.04 | $6.59 |
| Resistance Level | $5.39 | N/A |
| Average True Range (ATR) | 0.14 | 0.77 |
| MACD | -0.05 | 0.21 |
| Stochastic Oscillator | 4.00 | 69.04 |
Redwood Trust Inc is a specialty finance company focused on several distinct areas of housing credit. The company delivers customized housing credit investments to a diverse mix of investors through securitization platforms, whole-loan distribution activities, and its publicly traded securities. The company has four reportable segments: Sequoia Mortgage Banking, CoreVest Mortgage Banking, Redwood Investments, and Legacy Investments. Maximum revenue is generated from the Sequoia Mortgage Banking segment, comprising a mortgage loan conduit that acquires residential consumer loans from third-party originators for subsequent sale to whole loan buyers, securitization through its SEMT private-label securitization program, or transfer into its Redwood Investments portfolio.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.